arx517
arx517: sourced relationships with 1 company · 1 clinical trial tracked.
arx517 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could arx517 → AMAM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Ambrx Biopharma Cayman, Inc. (AMAM) Prostate cancer, including metastatic castration-resistant p… | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
Primary endpoint: Assess incidence of adverse events
Frequently asked questions
Which companies have sourced relationships with arx517?
arx517 has dated SEC/FDA relationship records for Ambrx Biopharma Cayman, Inc..
How many clinical trials involve arx517?
BioSniper tracks 1 clinical trial involving arx517.